Fredun Pharmaceuticals Ltd — Important, 25-05-2026: Company Update

Fredun Pharmaceuticals has released its audited financial results for Q4 FY26 and FY26, showcasing robust growth. For FY26, revenue increased 40% year-on-year to ₹639.12 Cr, with EBITDA surging 72% to ₹94.79 Cr, expanding margins to 14.8%. Net Profit grew nearly 60% to ₹33.21 Cr. The company's board has approved a dividend of ₹0.70 per share and bonus shares in a 2:1 ratio, pending shareholder approval. Strategic developments include launching new hormone therapy and wellness platforms, expanding manufacturing capacity, and an improved credit rating. This signals strengthening financial health and future growth initiatives.